المؤلفون: Olaya, María del Pilar, Vergel, Nadezdha Esperanza, López, Jose Luis, Viña, Dolores, Guerrero, Mario Francisco

المصدر: Brazilian Journal of Pharmaceutical Sciences. January 2020 56

مصطلحات موضوعية: Parkinson’s disease, Monoamine oxidase B, Coumarin, Mice, Reserpine, Levodopa, Carbidopa

وصف الملف: text/html

URL الوصول: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100508

المؤلفون: Munóz, Carol, Vergel, Nadezdha E., Aragón, Diana Marcela, Ospina, Luis Fernando

المصدر: Revista Colombiana de Ciencias Químico-Farmacéuticas; Vol. 38 Núm. 1 (2009) ; Revista Colombiana de Ciencias Químico-Farmacéuticas; v. 38 n. 1 (2009) ; Revista Colombiana de Ciencias Químico-Farmacéuticas; Vol. 38 No. 1 (2009) ; 1909-6356 ; 0034-7418

مصطلحات موضوعية: Hot Plate, Acetic acid induced writhing, Formalin Test, Physalis peruviana, Critoniella acuminata, Salvia rubescens, Placa caliente, formalina, contorsiones abdominales

وصف الملف: application/pdf; text/html

Relation: https://revistas.unal.edu.co/index.php/rccquifa/article/view/15426/16201; https://revistas.unal.edu.co/index.php/rccquifa/article/view/15426/36596; https://revistas.unal.edu.co/index.php/rccquifa/article/view/15426

الاتاحة: https://revistas.unal.edu.co/index.php/rccquifa/article/view/15426

المؤلفون: Rodriguez, Marisol, Vergel, Nadezdha, Ospina, Luis, Calle, Jairo, Pizón, Roberto

المصدر: Revista Colombiana de Ciencias Químico-Farmacéuticas; Vol. 34 Núm. 1 (2005) ; Revista Colombiana de Ciencias Químico-Farmacéuticas; v. 34 n. 1 (2005) ; Revista Colombiana de Ciencias Químico-Farmacéuticas; Vol. 34 No. 1 (2005) ; 1909-6356 ; 0034-7418

مصطلحات موضوعية: Elastase – myeloperoxidase - amarisolide – arbutin – ayapin - Critoniella acuminata -Physalis peruviana - Salvia rubescens, Elastasa – mieloperoxidasa - amarisolide – arbutina – ayapín - Critoniella acuminata - Physalis peruviana - Salvia rubescens

وصف الملف: application/pdf

Relation: https://revistas.unal.edu.co/index.php/rccquifa/article/view/1614/2277; https://revistas.unal.edu.co/index.php/rccquifa/article/view/1614

الاتاحة: https://revistas.unal.edu.co/index.php/rccquifa/article/view/1614

المؤلفون: Rodriguez, Marisol, Vergel, Nadezdha, Ospina, Luis, Calle, Jairo, Pizón, Roberto

وصف الملف: application/pdf

Relation: http://revistas.unal.edu.co/index.php/rccquifa/article/view/1614; Universidad Nacional de Colombia Revistas electrónicas UN Revista Colombiana de Ciencias Químico Farmacéuticas; Revista Colombiana de Ciencias Químico Farmacéuticas; Revista Colombiana de Ciencias Químico Farmacéuticas; Vol. 34, núm. 1 (2005) 0034-7418 1909-6356; Rodriguez, Marisol and Vergel, Nadezdha and Ospina, Luis and Calle, Jairo and Pizón, Roberto (2005) Evaluación de actividades enzimáticas elastasa y mieloperoxidasa como marcadores de desgranulación leucocitaria en modelos de inflamación aguda. Revista Colombiana de Ciencias Químico Farmacéuticas; Vol. 34, núm. 1 (2005) 0034-7418 1909-6356 .; https://repositorio.unal.edu.co/handle/unal/22884; http://bdigital.unal.edu.co/13919/

الاتاحة: https://repositorio.unal.edu.co/handle/unal/22884
http://bdigital.unal.edu.co/13919/

المؤلفون: Universidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas, Universidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, Pilar Olaya, María del, Vergel, Nadezdha Esperanza, López, Jose Luis, Viña Castelao, María Dolores

مصطلحات الفهرس: Parkinson’s disease, Monoamine oxidase B, Coumarin, Mice, Reserpine, Levodopa, Carbidopa, journal article

URL: http://hdl.handle.net/10347/21693
https://doi.org/10.1590/s2175-97902019000317609
https://doi.org/10.1590/s2175-97902019000317609

المؤلفون: Olaya, María del Pilar, Vergel, Nadezdha Esperanza, López, José Luis, Viña, María Dolores, Guerrero, Mario Francisco

المصدر: Biomedica; Vol. 39 No. 3 (2019); 491-501 ; Biomédica; Vol. 39 Núm. 3 (2019); 491-501 ; 2590-7379 ; 0120-4157

مصطلحات موضوعية: Parkinson’s disease, monoamine oxidase, coumarins, models, animal, reserpine, levodopa, haloperidol, antioxidants, enfermedad de Parkinson, monoaminooxidasa, cumarinas, modelos animales, reserpina, antioxidantes

وصف الملف: application/pdf; text/xml

Relation: https://revistabiomedica.org/index.php/biomedica/article/view/4299/4139; https://revistabiomedica.org/index.php/biomedica/article/view/4299/4413; Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson’s disease. Rev Neurol (Paris). 2016;172:14-26. https://doi.org/10.1016/j.neurol.2015.09.012; Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-6. https://doi.org/10.1212/01.wnl.0000247740.47667.03; Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA. 2014; 311:1670-83. https://doi.org/10.1001/jama.2014.3654; Alexi T, Borlongan C, Faull R, Williams C, Clark R, Gluckman P, et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases. Prog Neurobiol. 2000;60:409-70. https://doi.org/10.1016/S0301-0082(99)00032-5; Emborg M. Evaluation of animal models of Parkinson’s disease for neuroprotective strategies. J Neurosci Methods. 2004;139:121-43. https://doi.org/10.1016/j.jneumeth.2004.08.004; Gershanik OS. Improving L-dopa therapy: The development of enzyme inhibitors. Mov Disord. 2015;30:103-13. https://doi.org/10.1002/mds.26050; Finberg J. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B; focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014;143:133-52. https://doi.org/10.1016/j.pharmthera.2014.02.010; Ariza S, Rueda D, Rincón J, Linares E, Guerrero M. Efectos farmacológicos sobre el sistema nervioso central inducidos por cumarina aislada de Hygrophila tyttha Leonard. Vitae. 2007;14:51-8.; Vergel N, López J, Orallo F, Viña D, Buitrago D, Olmo E, et al. Antidepressant-like profile and MAO-A inhibitory activity of 4-propyl-2H-benzo[h]- chromen-2-one. Life Sci. 2010;86:819-24. https://doi.org/10.1016/j.lfs.2010.04.001; Matos M, Viña D, Picciau C, Orallo F, Santana L, Uriarte E. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009;19:5053-5. https://doi.org/10.1016/j.bmcl.2009.07.039; Matos M, Viña D, Quezada E, Picciau C, Delogu G, Orallo F, et al. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009;19:3268-70. https://doi.org/10.1016/j.bmcl.2009.04.085; Matos M, Viña D, Janeiro P, Borges F, Santana L, Uriarte E. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010;20:5157-60. https://doi.org/10.1016/j.bmcl.2010.07.013; Matos M, Viña D, Vázquez-Rodríguez S, Uriarte E, Santana L. Focusing on new monoamine oxidase inhibitors: Differently substituted coumarins as an interesting scaffold. Curr Top Med Chem. 2012;12:2210-39. https://doi.org/10.2174/1568026611212200008; Matos M, Vilar S, González-Franco R, Uriarte E, Santana L, Friedman C, et al. Novel (coumarin-3-yl) carbamates as selective MAO-B inhibitors: Synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study. Eur J Med Chem. 2013;63:151-61. https://doi.org/10.1016/j.ejmech.2013.02.009; Pisani L, Farina R, Nicolotti O, Gadaleta D, Soto-Otero R, Catto M, et al. In silico design of novel 2H-chromen-2-one derivatives as potent and selective MAO-B inhibitors. Eur J Med Chem. 2015;89:98-105. https://doi.org/10.1016/j.ejmech.2014.10.029; Epifano F, Molinaro G, Genovese S, Ngomba R, Nicoletti F, Curini M. Neuroprotective effect of prenyloxycoumarins from edible vegetables. Neurosci Lett. 2008;443:57-60. https://doi.org/10.1016/j.neulet.2008.07.062; Liu WB, Zhou J, Qu Y, Li X, Lu CT, Xie KL, et al. Neuroprotective effect of osthole on MPP+-induced cytotoxicity in PC12 cells via inhibition of mitochondrial dysfunction and ROS production. Neurochem Int. 2010;57:203-15. https://doi.org/10.1016/j.neuint.2010.05.011; Philippens I. Non-human primate models for Parkinson’s disease. Drug Discov Today Dis Models. 2008;5:105-11. https://doi.org/10.1016/j.ddmod.2008.06.004; Matos M, Rodríguez F, Borges F, Santana L, Uriarte E, Estrada M, et al. 3-Amidocoumarins as potential multifunctional agents against neurodegenerative diseases. Chem Med Chem. 2015;10:2071-9. https://doi.org/10.1002/cmdc.201500408; Aguirre P, García O, Tapia V, Muñoz Y, Cassels BK, Núñez MT. Neuroprotective effect of a new 7,8-dihydroxycoumarin-based Fe2+/Cu2+ chelator in cell and animal models of Parkinson’s disease. ACS Chem Neurosci. 2017;8:178-85. https://doi.org/10.1021/acschemneuro.6b00309; Reglodi D, Renaud J, Tamas A, Tizabi Y, Socías SB, Del-Bel E, et al. Novel tactics for neuroprotection in Parkinson’s disease: Role of antibiotics, polyphenols and neuropeptides. Prog Neurobiol. 2017;155:120-48. https://doi.org/10.1016/j.pneurobio.2015.10.004; Garazd M, Garazd Y, Ogorodniichuk A, Khilya V. Modified coumarins. Synthesis of substituted 5-(4-methoxyphenyl)-7H-furo [3,2-g] chromen-7-ones. Chem Nat Compd. 2002;38:539-48. https://doi.org/10.1023/A:1022626402415; National Center for Biotechnology Information. PubChem Open Chemistry Database Compound Summary for CID 608273. Accessed on: January 20, 2018. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/608273; Tadaiesky M, Andreatini R, Vital M. Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice. Eur J Pharmacol. 2006;535:199-207. https://doi.org/10.1016/j.ejphar.2006.02.004; Schmidt W, Mayerhofer A, Meyer A, Kovar K. Ecstasy counteracts catalepsy in rats, an antiparkinsonian effect? Neurosci Lett. 2002;330:251-4.; Wei L, Chen L. Effects of 5-HT in globus pallidus on haloperidol-induced catalepsy in rats. Neurosci Lett. 2009;454:49-52. https://doi.org/10.1016/j.neulet.2009.02.053; Hijova E, Nistiar F, Sipulova A. Changes in ascorbic acid and malondialdehyde in rats after exposure to mercury. Bratis Lek Listy. 2005;106:248-51.; Levine R, Garland D, Oliver C, Amici A, Climent I, Lenz A, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464-78. https://doi.org/10.1016/0076-6879(90)86141-H; Baltacioglu E, Akalin FA, Alver A, Deger O, Karabulut E. Protein carbonyl levels in serum and gingival crevicular fluid in patients with chronic periodontitis. Arch Oral Biol. 2008;53:716-22. https://doi.org/10.1016/j.archoralbio.2008.02.002; Yáñez M, Fraiz N, Cano E, Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun. 2006;344:688-95. https://doi.org/10.1016/j.bbrc.2006.03.190; Colpaert F. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rats. Neuropharmacology. 1987;26:1431-40.; Kaur S, Starr M. Antiparkinsonian action of dextramethorphan in the reserpine-treated mouse. Eur J Pharmacol. 1995;280:159-66.; Menzaghi F, Whelan K, Risbrough V, Rao T, Lloyd G. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson’s disease in rats. J. Pharmacol Exp Ther. 1997;280:393-401.; Foley P, Gerlach M, Youdim M, Riederer P. MAO-B inhibitors: Multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord. 2000;6;25-47. https://doi.org/10.1016/S1353-8020(99)00043-7; Fernández H, Chen J. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy. 2007;27:174S-85S. https://doi.org/10.1592/phco.27.12part2.174S; Fisher A, Biggs C, Eradiri O, Starr M. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: Evidence that behavior is dopamine independent. Neuroscience. 2000;95:97-111. https://doi.org/10.1016/S0306-4522(99)00406-6; Haleem DJ, Inam QU, Haleem MA. Effects of clinically relevant doses of methyphenidate on spatial memory, behavioral sensitization and open field habituation: A time related study. Behav Brain Res. 2015;281:208-14. https://doi.org/10.1016/j.bbr.2014.12.031; Deacon RM, Koros E, Bornemann KD, Rawlins JN. Aged Tg2576 mice are impaired on social memory and open field habituation tests. Behav Brain Res. 2009;197:466-8. https://doi.org/10.1016/j.bbr.2008.09.042; Wang X, Han C, Xu Y, Wu K, Chen S, Hu M, et al. Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson’s disease. Molecules. 2017;22:1-13. https://doi.org/10.3390/molecules22061010; Duty S, Jenner P. Animal models of Parkinson´s disease: A source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164:1357-91. https://doi.org/10.1111/j.1476-5381.2011.01426.x; Bishnoi M, Chopra K, Kulkarni S. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol. 2006;552:55-66. https://doi.org/10.1016/j.ejphar.2006.09.010; Bishnoi M, Chopra K, Kulkarni S. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia -A biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1130-8. https://doi.org/10.1016/j.pnpbp.2007.04.007; Martins M, Petronilho F, Gomes K, Dai-Pizzol F, Streck E, Quevedo J. Antipsychotic induced oxidative stress in rat brain. Neurotox Res. 2008;13:63-9. https://doi.org/10.1007/BF03033368; Naidu P, Singh A, Kulkarni S. Quercetin, a bioflavonoid attenuated haloperidol induced orofacial dyskinesia. Neuropharmacology. 2003;44:1100-6. https://doi.org/10.1016/S0028-3908(03)00101-1; Singh A, Naidu P, Kulkarni S. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. Eur J Pharmacol. 2003;477:87-94. https://doi.org/10.1016/S0014-2999(03)02124-1; Pavshintsev VV, Podshivalova LS, Frolova OY, Belopolskaya OA, Averina OA, Kushnir EA, et al. Effects of mitochondrial antioxidant SkQ1 on biochemical and behavioural parameters in a Parkinsonism model in mice. Biochemistry (Mosc). 2003;82:1513-20. https://doi.org/10.1134/S0006297917120100; Molina-Jiménez M F, Sánchez-Reus M I, Benedi J. Effect of fraxetin and myricetin on rotenone-induced cytotoxicity in SH-SY5Y cells: Comparison with N-acetylcysteine. Eur J Pharmacol. 2003;472:81-7. https://doi.org/10.1016/S0014-2999(03)01902-2; Kong LD, Tan RX, Woo AY, Cheng CH. Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: Implications for the treatment of affective disorders. Pharmacol Toxicol. 2001;88:75-80.; https://revistabiomedica.org/index.php/biomedica/article/view/4299

الاتاحة: https://revistabiomedica.org/index.php/biomedica/article/view/4299

Additional Titles: El análogo de cumarina 3-metil-7H-furo[3,2-g]cromen-7-ona, un posible agente antiparkinsoniano

المؤلفون: Olaya, María del Pilar, Vergel, Nadezdha Esperanza, López, José Luis, Viña, María Dolores, Guerrero, Mario Francisco

المصدر: Biomedica; Vol. 39 No. 3 (2019); 491-501; Biomédica; Vol. 39 Núm. 3 (2019); 491-501; 2590-7379; 0120-4157

مصطلحات الفهرس: Parkinson’s disease, monoamine oxidase, coumarins, models, animal, reserpine, levodopa, haloperidol, antioxidants, enfermedad de Parkinson, monoaminooxidasa, cumarinas, modelos animales, reserpina, antioxidantes, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion

URL: https://revistabiomedica.org/index.php/biomedica/article/view/4299
https://revistabiomedica.org/index.php/biomedica/article/view/4299/4139
https://revistabiomedica.org/index.php/biomedica/article/view/4299/4413
https://revistabiomedica.org/index.php/biomedica/article/view/4299/4139
https://revistabiomedica.org/index.php/biomedica/article/view/4299/4413
*ref*/Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson’s disease. Rev Neurol (Paris). 2016;172:14-26. https://doi.org/10.1016/j.neurol.2015.09.012
*ref*/Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-6. https://doi.org/10.1212/01.wnl.0000247740.47667.03
*ref*/Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA. 2014; 311:1670-83. https://doi.org/10.1001/jama.2014.3654
*ref*/Alexi T, Borlongan C, Faull R, Williams C, Clark R, Gluckman P, et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases. Prog Neurobiol. 2000;60:409-70. https://doi.org/10.1016/S0301-0082(99)00032-5
*ref*/Emborg M. Evaluation of animal models of Parkinson’s disease for neuroprotective strategies. J Neurosci Methods. 2004;139:121-43. https://doi.org/10.1016/j.jneumeth.2004.08.004
*ref*/Gershanik OS. Improving L-dopa therapy: The development of enzyme inhibitors. Mov Disord. 2015;30:103-13. https://doi.org/10.1002/mds.26050
*ref*/Finberg J. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B; focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014;143:133-52. https://doi.org/10.1016/j.pharmthera.2014.02.010
*ref*/Ariza S, Rueda D, Rincón J, Linares E, Guerrero M. Efectos farmacológicos sobre el sistema nervioso central inducidos por cumarina aislada de Hygrophila tyttha Leonard. Vitae. 2007;14:51-8.
*ref*/Vergel N, López J, Orallo F, Viña D, Buitrago D, Olmo E, et al. Antidepressant-like profile and MAO-A inhibitory activity of 4-propyl-2H-benzo[h]- chromen-2-one. Life Sci. 2010;86:819-24. https://doi.org/10.1016/j.lfs.2010.04.001
*ref*/Matos M, Viña D, Picciau C, Orallo F, Santana L, Uriarte E. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009;19:5053-5. https://doi.org/10.1016/j.bmcl.2009.07.039
*ref*/Matos M, Viña D, Quezada E, Picciau C, Delogu G, Orallo F, et al. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009;19:3268-70. https://doi.org/10.1016/j.bmcl.2009.04.085
*ref*/Matos M, Viña D, Janeiro P, Borges F, Santana L, Uriarte E. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010;20:5157-60. https://doi.org/10.1016/j.bmcl.2010.07.013
*ref*/Matos M, Viña D, Vázquez-Rodríguez S, Uriarte E, Santana L. Focusing on new monoamine oxidase inhibitors: Differently substituted coumarins as an interesting scaffold. Curr Top Med Chem. 2012;12:2210-39. https://doi.org/10.2174/1568026611212200008
*ref*/Matos M, Vilar S, González-Franco R, Uriarte E, Santana L, Friedman C, et al. Novel (coumarin-3-yl) carbamates as selective MAO-B inhibitors: Synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study. Eur J Med Chem. 2013;63:151-61. https://doi.org/10.1016/j.ejmech.2013.02.009
*ref*/Pisani L, Farina R, Nicolotti O, Gadaleta D, Soto-Otero R, Catto M, et al. In silico design of novel 2H-chromen-2-one derivatives as potent and selective MAO-B inhibitors. Eur J Med Chem. 2015;89:98-105. https://doi.org/10.1016/j.ejmech.2014.10.029
*ref*/Epifano F, Molinaro G, Genovese S, Ngomba R, Nicoletti F, Curini M. Neuroprotective effect of prenyloxycoumarins from edible vegetables. Neurosci Lett. 2008;443:57-60. https://doi.org/10.1016/j.neulet.2008.07.062
*ref*/Liu WB, Zhou J, Qu Y, Li X, Lu CT, Xie KL, et al. Neuroprotective effect of osthole on MPP+-induced cytotoxicity in PC12 cells via inhibition of mitochondrial dysfunction and ROS production. Neurochem Int. 2010;57:203-15. https://doi.org/10.1016/j.neuint.2010.05.011
*ref*/Philippens I. Non-human primate models for Parkinson’s disease. Drug Discov Today Dis Models. 2008;5:105-11. https://doi.org/10.1016/j.ddmod.2008.06.004
*ref*/Matos M, Rodríguez F, Borges F, Santana L, Uriarte E, Estrada M, et al. 3-Amidocoumarins as potential multifunctional agents against neurodegenerative diseases. Chem Med Chem. 2015;10:2071-9. https://doi.org/10.1002/cmdc.201500408
*ref*/Aguirre P, García O, Tapia V, Muñoz Y, Cassels BK, Núñez MT. Neuroprotective effect of a new 7,8-dihydroxycoumarin-based Fe2+/Cu2+ chelator in cell and animal models of Parkinson’s disease. ACS Chem Neurosci. 2017;8:178-85. https://doi.org/10.1021/acschemneuro.6b00309
*ref*/Reglodi D, Renaud J, Tamas A, Tizabi Y, Socías SB, Del-Bel E, et al. Novel tactics for neuroprotection in Parkinson’s disease: Role of antibiotics, polyphenols and neuropeptides. Prog Neurobiol. 2017;155:120-48. https://doi.org/10.1016/j.pneurobio.2015.10.004
*ref*/Garazd M, Garazd Y, Ogorodniichuk A, Khilya V. Modified coumarins. Synthesis of substituted 5-(4-methoxyphenyl)-7H-furo [3,2-g] chromen-7-ones. Chem Nat Compd. 2002;38:539-48. https://doi.org/10.1023/A:1022626402415
*ref*/National Center for Biotechnology Information. PubChem Open Chemistry Database Compound Summary for CID 608273. Accessed on: January 20, 2018. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/608273
*ref*/Tadaiesky M, Andreatini R, Vital M. Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice. Eur J Pharmacol. 2006;535:199-207. https://doi.org/10.1016/j.ejphar.2006.02.004
*ref*/Schmidt W, Mayerhofer A, Meyer A, Kovar K. Ecstasy counteracts catalepsy in rats, an antiparkinsonian effect? Neurosci Lett. 2002;330:251-4.
*ref*/Wei L, Chen L. Effects of 5-HT in globus pallidus on haloperidol-induced catalepsy in rats. Neurosci Lett. 2009;454:49-52. https://doi.org/10.1016/j.neulet.2009.02.053
*ref*/Hijova E, Nistiar F, Sipulova A. Changes in ascorbic acid and malondialdehyde in rats after exposure to mercury. Bratis Lek Listy. 2005;106:248-51.
*ref*/Levine R, Garland D, Oliver C, Amici A, Climent I, Lenz A, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464-78. https://doi.org/10.1016/0076-6879(90)86141-H
*ref*/Baltacioglu E, Akalin FA, Alver A, Deger O, Karabulut E. Protein carbonyl levels in serum and gingival crevicular fluid in patients with chronic periodontitis. Arch Oral Biol. 2008;53:716-22. https://doi.org/10.1016/j.archoralbio.2008.02.002
*ref*/Yáñez M, Fraiz N, Cano E, Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun. 2006;344:688-95. https://doi.org/10.1016/j.bbrc.2006.03.190
*ref*/Colpaert F. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rats. Neuropharmacology. 1987;26:1431-40.
*ref*/Kaur S, Starr M. Antiparkinsonian action of dextramethorphan in the reserpine-treated mouse. Eur J Pharmacol. 1995;280:159-66.
*ref*/Menzaghi F, Whelan K, Risbrough V, Rao T, Lloyd G. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson’s disease in rats. J. Pharmacol Exp Ther. 1997;280:393-401.
*ref*/Foley P, Gerlach M, Youdim M, Riederer P. MAO-B inhibitors: Multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord. 2000;6;25-47. https://doi.org/10.1016/S1353-8020(99)00043-7
*ref*/Fernández H, Chen J. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy. 2007;27:174S-85S. https://doi.org/10.1592/phco.27.12part2.174S
*ref*/Fisher A, Biggs C, Eradiri O, Starr M. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: Evidence that behavior is dopamine independent. Neuroscience. 2000;95:97-111. https://doi.org/10.1016/S0306-4522(99)00406-6
*ref*/Haleem DJ, Inam QU, Haleem MA. Effects of clinically relevant doses of methyphenidate on spatial memory, behavioral sensitization and open field habituation: A time related study. Behav Brain Res. 2015;281:208-14. https://doi.org/10.1016/j.bbr.2014.12.031
*ref*/Deacon RM, Koros E, Bornemann KD, Rawlins JN. Aged Tg2576 mice are impaired on social memory and open field habituation tests. Behav Brain Res. 2009;197:466-8. https://doi.org/10.1016/j.bbr.2008.09.042
*ref*/Wang X, Han C, Xu Y, Wu K, Chen S, Hu M, et al. Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson’s disease. Molecules. 2017;22:1-13. https://doi.org/10.3390/molecules22061010
*ref*/Duty S, Jenner P. Animal models of Parkinson´s disease: A source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164:1357-91. https://doi.org/10.1111/j.1476-5381.2011.01426.x
*ref*/Bishnoi M, Chopra K, Kulkarni S. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol. 2006;552:55-66. https://doi.org/10.1016/j.ejphar.2006.09.010
*ref*/Bishnoi M, Chopra K, Kulkarni S. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia -A biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1130-8. https://doi.org/10.1016/j.pnpbp.2007.04.007
*ref*/Martins M, Petronilho F, Gomes K, Dai-Pizzol F, Streck E, Quevedo J. Antipsychotic induced oxidative stress in rat brain. Neurotox Res. 2008;13:63-9. https://doi.org/10.1007/BF03033368
*ref*/Naidu P, Singh A, Kulkarni S. Quercetin, a bioflavonoid attenuated haloperidol induced orofacial dyskinesia. Neuropharmacology. 2003;44:1100-6. https://doi.org/10.1016/S0028-3908(03)00101-1
*ref*/Singh A, Naidu P, Kulkarni S. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. Eur J Pharmacol. 2003;477:87-94. https://doi.org/10.1016/S0014-2999(03)02124-1
*ref*/Pavshintsev VV, Podshivalova LS, Frolova OY, Belopolskaya OA, Averina OA, Kushnir EA, et al. Effects of mitochondrial antioxidant SkQ1 on biochemical and behavioural parameters in a Parkinsonism model in mice. Biochemistry (Mosc). 2003;82:1513-20. https://doi.org/10.1134/S0006297917120100
*ref*/Molina-Jiménez M F, Sánchez-Reus M I, Benedi J. Effect of fraxetin and myricetin on rotenone-induced cytotoxicity in SH-SY5Y cells: Comparison with N-acetylcysteine. Eur J Pharmacol. 2003;472:81-7. https://doi.org/10.1016/S0014-2999(03)01902-2
*ref*/Kong LD, Tan RX, Woo AY, Cheng CH. Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: Implications for the treatment of affective disorders. Pharmacol Toxicol. 2001;88:75-80.

Alternate Title: Análogo de cumarina 3-metil-7H-furo[3,2-g]cromen-7-ona, un posible agente antiparquinsoniano.

المؤلفون: del Pilar Olaya, María¹ mpolayao@unal.edu.co, Esperanza Vergel, Nadezdha¹, Luis López, José², Viña, María³, Francisco Guerrero, Mario¹

المصدر: Revista Biomedica. 2019, Vol. 39 Issue 3, p2-30. 29p. 6 Graphs.

مصطلحات موضوعية: *ANTIPARKINSONIAN agents, *COUMARINS, *PARKINSON'S disease treatment, *MONOAMINE oxidase, *HALOPERIDOL

Alternate Title: El análogo de cumarina 3-metil-7H-furo[3,2-g]cromen-7-ona, un posible agent antiparkinsoniano. (Spanish)

المؤلفون: del Pilar Olaya, María, Esperanza Vergel, Nadezdha, Luis López, José, Dolores Viña, María, Francisco Guerrero, Mario

المصدر: Biomédica: Revista del Instituto Nacional de Salud; sep2019, Vol. 39 Issue 3, p491-501, 11p

مصطلحات موضوعية: ANTIPARKINSONIAN agents, COUMARINS, MONOAMINE oxidase inhibitors, MONOAMINE oxidase, PARKINSON'S disease, NEURODEGENERATION

المؤلفون: Giraldo, Sara E., Rincón, Javier, Guerrero, Mario F., López, Isabel, Jiménez, Ignacio, Marder, Nora Mariel, Wasowski, Cristina Lucia N., Vergel, Nadezdha E.

مصطلحات موضوعية: Otras Ciencias de la Salud, ANTICONVULSANT, CIENCIAS MÉDICAS Y DE LA SALUD, GABA A RECEPTOR, TONIC-CLONIC-EPILEPSY, Ciencias de la Salud, VALERIANA

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______3498::35126dd2509e7bafa136e6aa63135515
http://www.latamjpharm.org/previous_issue.php?vol=32&num=8

المؤلفون: Giraldo, Sara Emilia, Rincón, Javier, Puebla, Pilar, Marder, Mariel, Wasowski, Cristina, Vergel, Nadezdha, Guerrero, Mario Francisco

المصدر: Biomedica; Vol. 30 No. 2 (2010); 245-50 ; Biomédica; Vol. 30 Núm. 2 (2010); 245-50 ; 2590-7379 ; 0120-4157 ; 10.7705/biomedica.v30i2

مصطلحات موضوعية: valerian, medicine, traditional, valproic acid, anticonvulsants, epilepsy, tonic-clonic, valeriana, medicina tradicional, ácido valproico, anticonvulsivos, epilepsia, epilepsia tónico-clónica

وصف الملف: application/pdf

Relation: https://revistabiomedica.org/index.php/biomedica/article/view/187/178; https://revistabiomedica.org/index.php/biomedica/article/view/187/368; Eadie MJ. Could Valerian have been the first anticonvulsant? Epilepsia. 2004;45:1338-43. 2. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol.1999;51:505-12. 3. Fernández S, Wasowski C, Paladini AC, Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav. 2004;77:399-04. 4. García H. Flora medicinal de Colombia, Botánica Médica. Instituto de Ciencias Naturales, Universidad Nacional de Colombia, Bogotá: Mundo Editores; 1992. Tomo 3. p. 254-62. 5. Arévalo D, Martínez C, Rincón J, Guerrero MF. Fracción alcaloidal obtenida de Valeriana pavonii Poepp con actividad anticonvulsivante. Rev Colomb Ciencias Quím Farm. 2006;35:168-76. 6. Célis CT, Rincón J, Guerrero MF. Actividad farmacológica sobre el sistema nervioso central del extracto etanólico y de la fracción alcaloidal de Valeriana pavonii. Rev Colomb Ciencias Quím Farm. 2007;36:11-22. 7. Pradilla G, Vesga B, León-Sarmiento F, Grupo Geneco. Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Rev Panam Salud Pública. 2003;14:104-11. 8. Burneo J, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res. 2005; 66:63-74. 9. Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci. 2002;23:113-8. 10. Schachter SC. Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics. 2009;6:415-20. 11. Giardina WJ. Models of epilepsy: Electroshock and chemical induced convulsions in the mouse. En: Current Protocols in Pharmacology. New York: John Wiley & Sons; 2000. Volume 5. p. 1-22. 12. Wolf P. Basic principles of the ILAE syndrome classification. Epilepsy Res. 2006;70(Suppl.1):S20-6. 13. Swinyard EA, Woodhead JH. Experimental detection, quantification, and evaluation of anticonvulsants. En: Woodbury DM, Penry JK, Pippenger CE. Antiepileptic Drugs. 2nd edition. New York: Raven Press; 1982. p. 111-26. 14. Bialer M, Johannessenb SI, Kupferbergc HJ, Levyd RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the seventh EILAT conference (EILAT VII). Epilepsy Res. 2004;61:1-48. 15. Pollard JR, French J. Antiepileptic drugs in development. Lancet Neurol. 2006;5:1064-7. 16. America´s Pharmaceutical Research Companies. Pharmaceutical companies researching and developing more than 500 medicines for neurological disorders. En: Report, medicines in development for neurological disorders. Washington, D.C.: Pharma, New Medicines, New Hope; 2008. p. 37. 17. Bialer M, Yagen B. Valproic acid: second generation. Neurotherapeutics. 2007;4:130-7. 18. Isoherranen N, Yagen B, Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr Opin Neurol. 2003;16:203-11. 19. Nau H, Siemens H. Differentiation between valproate-induced antiepileptic effect, teratogenicity and hepatotoxicity. Pharm Weekbl Sci. 1992;14:101-5. 20. Bucková A, Grznár K, Haladová M, Eisenreichová E. Active principles in Valeriana officinalis L. Cesk Farm. 1977;26:308-9.; https://revistabiomedica.org/index.php/biomedica/article/view/187

الاتاحة: https://revistabiomedica.org/index.php/biomedica/article/view/187

المؤلفون: Vergel, Nadezdha E., López, José L., Orallo, Francisco, Viña, Dolores, Buitrago, Diana M., del Olmo, Esther, Mico, Juan A., Guerrero, Mario F.

المصدر: Life Sciences ; volume 86, issue 21-22, page 819-824 ; ISSN 0024-3205

الاتاحة: http://dx.doi.org/10.1016/j.lfs.2010.04.001
https://api.elsevier.com/content/article/PII:S0024320510001591?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0024320510001591?httpAccept=text/plain

المؤلفون: OSPINA G, Luis F, ARAGÓN N, Diana M, VERGEL, Nadezdha E, ISAZA M, Gustavo, PÉREZ C, Jorge E

المصدر: Vitae, Volume: 18, Issue: 1, Pages: 49-55, Published: APR 2011

مصطلحات موضوعية: Tabebuia chrysantha, reactive oxygen species, inflammation, inflamación, Phenax rugosus, especies de oxígeno reactivas

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______618::7ed7a41e8bd56bfa34610443fb40a565
http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-40042011000100007&lng=en&tlng=en

المؤلفون: Giraldo, Sara Emilia, Rincón, Javier, Puebla, Pilar, Marder, Mariel, Wasowski, Cristina, Vergel, Nadezdha, Guerrero, Mario Francisco

المصدر: Biomédica, Volume: 30, Issue: 2, Pages: 245-250, Published: JUN 2010

مصطلحات موضوعية: medicina tradicional, valeriana, epilepsia tónico-clónica, valproic acid, epilepsy, tonic-clonic, anticonvulsants, epilepsy, valerian, ácido valproico, epilepsia, anticonvulsivos, medicine, traditional

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______618::fc93cd8645e0ddfe84fd2548318345f0
http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572010000200011&lng=en&tlng=en

المؤلفون: Muñoz, Carol E, Vergel, Nadezdha E, Cabral, Pablo, Aragón, Diana Marcela, Ospina, Luis Fernando

المصدر: Revista Colombiana de Ciencias Químico-Farmacéuticas, Volume: 38, Issue: 1, Pages: 31-41, Published: JAN 2009

مصطلحات موضوعية: contorsiones abdominales, Salvia rubescens, Acetic acid induced writhing, Formalin Test, Placa caliente, Hot Plate, Critoniella acuminata, Physalis peruviana, formalina

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______618::e803548c5f45604713356cfa303689db
http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0034-74182009000100003&lng=en&tlng=en

Additional Titles: Isovaleramida, principio anticonvulsivo aislado de Valeriana pavonii

المؤلفون: Giraldo, Sara Emilia, Rincón, Javier, Puebla, Pilar, Marder, Mariel, Wasowski, Cristina, Vergel, Nadezdha, Guerrero, Mario Francisco

المصدر: Biomedica; Vol. 30 No. 2 (2010); 245-50; Biomédica; Vol. 30 Núm. 2 (2010); 245-50; 2590-7379; 0120-4157; 10.7705/biomedica.v30i2

مصطلحات الفهرس: valerian, medicine, traditional, valproic acid, anticonvulsants, epilepsy, tonic-clonic, valeriana, medicina tradicional, ácido valproico, anticonvulsivos, epilepsia, epilepsia tónico-clónica, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion

URL: https://revistabiomedica.org/index.php/biomedica/article/view/187
https://revistabiomedica.org/index.php/biomedica/article/view/187/178
https://revistabiomedica.org/index.php/biomedica/article/view/187/368
https://revistabiomedica.org/index.php/biomedica/article/view/187/178
https://revistabiomedica.org/index.php/biomedica/article/view/187/368
*ref*/Eadie MJ. Could Valerian have been the first anticonvulsant? Epilepsia. 2004;45:1338-43.2. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol.1999;51:505-12.3. Fernández S, Wasowski C, Paladini AC, Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav. 2004;77:399-04.4. García H. Flora medicinal de Colombia, Botánica Médica. Instituto de Ciencias Naturales, Universidad Nacional de Colombia, Bogotá: Mundo Editores; 1992. Tomo 3. p. 254-62.5. Arévalo D, Martínez C, Rincón J, Guerrero MF. Fracción alcaloidal obtenida de Valeriana pavonii Poepp con actividad anticonvulsivante. Rev Colomb Ciencias Quím Farm. 2006;35:168-76.6. Célis CT, Rincón J, Guerrero MF. Actividad farmacológica sobre el sistema nervioso central del extracto etanólico y de la fracción alcaloidal de Valeriana pavonii. Rev Colomb Ciencias Quím Farm. 2007;36:11-22.7. Pradilla G, Vesga B, León-Sarmiento F, Grupo Geneco. Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Rev Panam Salud Pública. 2003;14:104-11.8. Burneo J, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res. 2005; 66:63-74.9. Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci. 2002;23:113-8.10. Schachter SC. Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics. 2009;6:415-20.11. Giardina WJ. Models of epilepsy: Electroshock and chemical induced convulsions in the mouse. En: Current Protocols in Pharmacology. New York: John Wiley & Sons; 2000. Volume 5. p. 1-22.12. Wolf P. Basic principles of the ILAE syndrome classification. Epilepsy Res. 2006;70(Suppl.1):S20-6.13. Swinyard EA, Woodhead JH. Experimental detection, quantification, and evaluation of

المؤلفون: Pilar Olaya, María del, Vergel, Nadezdha Esperanza, López, Jose Luis, Viña Castelao, María Dolores

المساهمون: Universidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas, Universidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica

مصطلحات موضوعية: Parkinson’s disease, Monoamine oxidase B, Coumarin, Mice, Reserpine, Levodopa, Carbidopa

وصف الملف: application/pdf

Relation: https://doi.org/10.1590/s2175-97902019000317609; OLAYA, María del Pilar et al. 8-Propyl-6H-[1,3]dioxolo[4,5-g]chromen-6-one: A new coumarin with monoamine oxidase B inhibitory activity and possible anti-parkinsonian effects. Braz. J. Pharm. Sci. [online]. 2020, vol.56 [cited 2020-04-23], e17609. Available from: . Epub Mar 16, 2020. ISSN 2175-9790. https://doi.org/10.1590/s2175-97902019000317609; http://hdl.handle.net/10347/21693

الاتاحة: http://hdl.handle.net/10347/21693
https://doi.org/10.1590/s2175-97902019000317609

المؤلفون: Giraldo, Sara E., Rincón, Javier, Guerrero, Mario F., López, Isabel, Jiménez, Ignacio, Marder, Nora Mariel, Wasowski, Cristina Lucia N., Vergel, Nadezdha E.

مصطلحات موضوعية: Anticonvulsant, Gaba a Receptor, Tonic-Clonic-Epilepsy, Valeriana, https://purl.org/becyt/ford/3.3, https://purl.org/becyt/ford/3

وصف الملف: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/url/http://www.latamjpharm.org/previous_issue.php?vol=32&num=8; http://hdl.handle.net/11336/8514; Giraldo, Sara E.; Rincón, Javier; Guerrero, Mario F.; López, Isabel; Jiménez, Ignacio; et al.; Valepotriate Hydrines Isolated from an Anticonvulsant Fraction of Valeriana pavonii Poepp. & Endl; Colegio Farmaceuticos Provincia de Buenos Aires; Latin American Journal of Pharmacy; 32; 8-2013; 1224-1230

الاتاحة: http://hdl.handle.net/11336/8514

المؤلفون: Giraldo, Sara Emilia, Bedoya, Mauricio, Peña Varas, Carlos, Santana, Paula A., Bazzocchi, Isabel L., Jiménez, Ignacio A., Marder, Nora Mariel, Vergel, Nadezdha E., Guerrero, Mario F., Ramírez, David

مصطلحات موضوعية: ENSEMBLE MOLECULAR DOCKING, GABAA MODULATORS, GABAA RECEPTOR, IRIDOIDS, VALERIAN, https://purl.org/becyt/ford/1.4, https://purl.org/becyt/ford/1

وصف الملف: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/url/https://jppres.com/jppres/iridoid-esters-from-valeriana-pavonii-as-gabaa-modulators/; http://hdl.handle.net/11336/227836; Giraldo, Sara Emilia; Bedoya, Mauricio; Peña Varas, Carlos; Santana, Paula A.; Bazzocchi, Isabel L.; et al.; Iridoid esters from Valeriana pavonii Poepp. & Endl. as GABAA modulators: Structural insights in their binding mode and structure-activity relationship; Asociación Académica de Ciencias Farmacéuticas de Antofagasta; Journal of Pharmacy and Pharmacognosy Research; 11; 3; 5-2023; 367-380; CONICET Digital; CONICET

الاتاحة: http://hdl.handle.net/11336/227836

المؤلفون: Giraldo, Sara Emilia, Rincón, Javier, Puebla, Pilar, Marder, Nora Mariel, Wasowski, Cristina Lucia N., Vergel, Nadezdha, Guerrero, Mario Francisco

مصطلحات موضوعية: Valeriana, Medicina tradicional, Ácido valproico, Anticonvulsivos, Epilepsia, Epilepsia tónico clónica, https://purl.org/becyt/ford/1.4, https://purl.org/becyt/ford/1

وصف الملف: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/url/http://www.revistabiomedica.org/index.php/biomedica/article/view/187; info:eu-repo/semantics/altIdentifier/url/http://ref.scielo.org/d39vnv; http://hdl.handle.net/11336/18247; Giraldo, Sara Emilia; Rincón, Javier; Puebla, Pilar; Marder, Nora Mariel; Wasowski, Cristina Lucia N.; et al.; Isovaleramida, principio anticonvulsivo aislado de Valeriana pavonii; Instituto Nacional de Salud; Biomédica; 30; 2; 4-2010; 245-250; CONICET Digital; CONICET

الاتاحة: http://hdl.handle.net/11336/18247